RAPID Pharmaceuticals

RAPID Pharmaceuticals was a Swiss biotechnology company focused on the development of novel peptide therapeutics for neurodegenerative and inflammatory diseases. The company's lead candidate, RAP-103, is a synthetic peptide analog of Peptide T designed to act as a CCR5 antagonist and inhibit neuroinflammation. Clinical development efforts primarily targeted neuropathic pain and HIV-associated neurocognitive disorder (HAND), reaching Phase 2 trials. The company's scientific foundation was built upon the research of Dr. Candace Pert and Dr. Michael Ruff concerning chemokine receptor signaling in the central nervous system. RAPID Pharmaceuticals AG was headquartered in Zug, Switzerland, but has since been liquidated.